Abstracts

184 – Most With HIV Viremia Are Not in Care Despite High ART Coverage: A Population-Based Study in Uganda

Background As ART coverage expands in Africa, a greater proportion of persons remaining with viremia are predicted to be HIV serostatus aware and treatment-experienced, potentially reducing the need for population surveillance and community outreach. However, population-level data on the care status of persons with viremia remains limited in African settings achieving “95-95-95” treatment targets.  Methods…

165 – Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV

Background HIV infection significantly increases carcinogenesis following HPV infection. The impact of this relationship on the cervical cancer burden is well documented. Less is known on HPV non-cervical cancers including anal, oropharyngeal, vaginal, vulvar and penile cancers. The World Health Organisation (WHO) aims to vaccinate 90% of girls under 15 against HPV, yet global vaccine…

119 – Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH

Background Drug-drug interactions (DDIs) between contraceptives and antiretroviral therapy (ART) may increase the risk of unintended pregnancy and side effects. The levonorgestrel (LNG) implant and depot medroxyprogesterone acetate (DMPA) injectable are commonly used contraceptives in women living with HIV (WLWH), but pharmacokinetic (PK) data evaluating DDIs between dolutegravir (DTG) and LNG or MPA are lacking.…

162 – DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC

Background Doxycycline post-exposure prophylaxis (DoxyPEP) use can significantly reduce the incidence of bacterial sexually transmitted infections (STIs), yet uptake has been low among people with HIV (PWH). In Washington, DC, high rates of STIs have been observed among PWH. We assessed STI diagnosis rates, DoxyPEP eligibility, use, and the potential impact of DoxyPEP prescribing on…

181 – Semaglutide Stabilizes Epigenetic Aging in People With HIV-Associated Lipohypertrophy

Background Semaglutide, a GLP-1 receptor agonist, is known to reduce weight and improve cardiometabolic disease outcomes. In a recent randomized, double-blind, placebo-controlled phase 2b clinical trial, we observed significant effects of once-weekly semaglutide over 32 weeks on weight and visceral adiposity in people on stable antiretroviral therapy with HIV-associated lipohypertrophy. Semaglutide has been proposed to have…

178 – Plaque, Inflammation, Subclinical Myocardial Injury, and MACE in the REPRIEVE Mechanistic Substudy

Background REPRIEVE established that pitavastatin prevents major adverse cardiovascular events (MACE) and reduces noncalcified coronary plaque (NCP) on coronary CT angiography, in low-moderate risk PWH. We leveraged the REPRIEVE Mechanistic Substudy to assess for the first time the relationship of coronary plaque and indices of inflammation and subclinical myocardial injury with MACE and the effects…

175 – Major Improvement in Age-Related Health Outcomes in People Living With HIV: An 18-Year Cohort Study

Background Antiretroviral therapy (ART) has transformed HIV from a life-threatening infection into a manageable chronic condition, allowing people living with HIV (PLWH) to have a significantly longer lifespan. However, as this population ages, they become increasingly susceptible to non-AIDS-related comorbidities typically associated with aging. Understanding the evolving patterns of these age-related conditions is essential to…

180 – Prognostic Value of Epigenetic Age Acceleration in People With Well-Controlled HIV Infection

Background Epigenetic age acceleration has prognostic value in the general population. However, its role in predicting clinical outcomes in people with HIV (PWH) with long-term virological suppression remains unclear Methods Retrospective cohort of PWH with long-term virological suppression, followed at a single HIV unit. Blood DNA methylation was assessed using the Illumina Infinium MethylationEPIC BeadChip,…